ReviewCellular signalling2009
Targeting EGFR resistance networks in head and neck cancer.
Review in Cellular signalling, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 74 citations in OpenAlex.
- Single-cell profiling of ERBB family receptors identifies ERBB3 as a key regulator in head and neck squamous cell carcinoma progression.Discover oncology · 2025Article
- Network pharmacological analysis andOpen medicine (Warsaw, Poland) · 2025Article
- Decoding the research landscape of drug resistance and therapeutic approaches in head and neck cancer: a bibliometric analysis from 2000 to 2023.Frontiers in pharmacology · 2024Article
- Extracellular cell matrix stiffness-driven drug resistance of breast cancer cells via EGFR activation.Mechanobiology in medicine · 2023Article
- Fibromodulin overexpression drives oral squamous cell carcinoma via activating downstream EGFR signaling.iScience · 2023Article
- Article
- Article
- Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes.Theranostics · 2022Article
- Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation.Advanced drug delivery reviews · 2021Review
- Transcription factor HBP1 is a direct anti-cancer target of transcription factor FOXO1 in invasive oral cancer.Oncotarget · 2017Article
- Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells.Anti-cancer agents in medicinal chemistry · 2017Article
- Article
- Quercetin suppresses cellular migration and invasion in human head and neck squamous cell carcinoma (HNSCC).BioMedicine · 2016Article
- Toward Signaling-Driven Biomarkers Immune to Normal Tissue Contamination.Cancer informatics · 2016Article
- Genomic insights into head and neck cancer.Cancers of the head & neck · 2016Article
- Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling.Scientific reports · 2015Article
- Article
- Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.World journal of gastroenterology · 2014Review
- The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.Journal of gastroenterology · 2014Review
- Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.The FEBS journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
A core set of oncoproteins is overexpressed or functionally activated in many types of cancer, and members of this group have attracted significant interest as subjects for development of targeted therapeutics. For some oncoproteins such as EGFR/ErbB1, both small molecule and antibody agents have been developed and applied in the clinic for over a decade. Analysis of clinical outcomes has revealed an initially unexpected complexity in the response of patients to these agents. Diverse factors, including developmental lineage of the tumor progenitor cell, co-mutation or epigenetic modulation of genes encoding proteins in an extended EGFR signaling network or regulating core survival responses in individual tumors, and environmental factors including inflammatory agents and viral infection, all have been identified as modulating response to treatment with EGFR-targeted drugs. Second and third generation therapeutic strategies increasingly incorporate knowledge of cancer type-specific signaling environments, in a more personalized treatment approach. This review takes squamous cell carcinoma of the head and neck (SCCHN) as a specific example of an EGFR-involved cancer with idiosyncratic biological features that influence design of treatment modalities, with particular emphasis on commonalities and differences with other cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.